An updated meta-analysis of 35 randomised trials including 114 592 people found that new-onset atrial fibrillation risk rose only in participants at high cardiovascular risk taking more than 1500 mg/d of EPA/DHA (odds ratio 1.43, absolute risk difference 0.8%). Lower doses showed no significant increase, even in high-risk groups.
What it shows: Pooled randomised trial data are strong, but this is a subgroup-defined finding across 35 heterogeneous trials in people aged 50 and over, with published and unpublished data combined; the authors call for prospective studies weighing the risk against omega-3's benefits.Study · Circ Arrhythm Electrophysiol